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Abstract 
Background: Aspergillosis of Central Nervous System (CNS) is a highly lethal infection in patients with leukemia and 
Stem Cell Transplantation (SCT).
Methods: Case reports of CNS aspergillosis in patients with leukemia and SCT published between 1990 and August 
2020 were gathered using a structured search through PubMed/Medline.
Results: Sixty-seven cases were identified over the searches of the PubMed bibliographic database and then, 59 
cases were included in the final analysis. Europe had the largest share of cases at 57.6% (34 reports), followed by 
Americas and Asia. Affected patients were predominantly males (58.6%) and the mean age of the patients was 
36.1 years, while 62.7% of the patients were under the age of 50 years. The most common leukemia types include 
Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), and Acute Myeloid Leukemia (AML) at 
43.4%, 27.4%, and 23.5%, respectively. Furthermore, stem cell transplantation was reported in 11 cases. The overall 
mortality was 33%; however, the attributable mortality rate of CNS aspergillosis was 24.5%. Altered mental status, 
hemiparesis, cranial nerve palsies, and seizures were the clearest manifestations of infection and lung involvement 
reported in 57% of the patients. Histopathologic examination led to the diagnosis of infection in 57% of the patients 
followed by culture (23.7%), galactomannan assay (8.5%), and molecular method (3.3%). Amphotericin B and voricon-
azole were the most frequently used drugs for infection treatment. Good results were not obtained in one-third of the 
patients treated by voriconazole. Finally, neurosurgical intervention was used for 23 patients (39%).
Conclusion: CNS aspergillosis is a rapidly progressive infection in leukemic patients. Thus, these patients should be 
followed up more carefully. Furthermore, management of induction chemotherapy, use of different diagnostic meth-
ods, and use of appropriate antifungal can lead to infection control.
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Introduction
Aspergillus is a branching septate filamentous fungus that 
can induce invasive, lethal infections in immune-deficient 
patients. Among the many species that are identified 
and recognized, Aspergillus fumigatus is by far the most 
common species Shariati A, Moradabadi A, Chegini Z, 
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Khoshbayan A and Didehdar M [1]. Specifically, Asper-
gillus species can infect respiratory and gastrointestinal 
tracts and skin, and in patients with immunodeficiency, 
other forms of the disease can occur. It is quite rare for 
the Invasive Central Nervous System (CNS) to become 
subjected to aspergillosis and this phenomenon con-
stitutes about 10–20% of all invasive aspergillosis cases 
with poor prognosis and significant mortality [2]. Asper-
gillus spp. are common in the environment (soil, dust, 
plants, and decaying vegetable matter) that are inhaled 
by breathing normal air, and the lungs have the highest 
chance of exposure to infection [3]. Thus, the portal of 
entry for Aspergillus usually lies in the respiratory tract 
and CNS involvement arises as a result of hematogenous 
spreading from the lung or through direct invasion of 
the adjacent cranial structure, surgery, contamination 
of indwelling catheters, and iatrogenic or penetrating 
trauma [4]. If aspergillosis already invades the paranasal 
sinuses or palate, it might penetrate the ethmoid sinuses 
and cribriform plate all the way into the intracranial com-
partment in which meninges, nerves, lymphatic chan-
nels, and blood vessels can become involved [5, 6]. Its 
extension to the surrounding neural tissues and the ves-
sel wall erosion by hyphal would promote meningitis, 
hemorrhage, necrosis, vasculitis, and infarction. When 
Aspergillus wears away the arterial wall and attacks the 
infarcted brain, the sterile infarct will convert to septic 
infarct and abscess. Thus, meningitis, cerebral blood ves-
sel invasion with secondary infection or hemorrhage, and 
single or multiple brain abscesses are the highly prevalent 
forms of CNS aspergillosis reported in patients [7, 8].
Persistent and profound neutropenia is the most signif-
icant risk factor in invasive aspergillosis; thus, this infec-
tion predominantly occurs in immune-compromised 
hosts. In this regard, patients with leukemia, recipients of 
bone marrow transplant, and patients exposed to alloge-
neic hematopoietic Stem Cell Transplantation (SCT) have 
a very high chance of developing invasive CNS aspergil-
losis [1, 9]. For patients with leukemia, especially Acute 
Lymphoblastic and Myeloid Leukemia  (ALL and AML), 
by receiving intensive cytotoxic chemotherapy and sev-
eral previous chemotherapy regimens, immunodepres-
sion with hypogammaglobinemia inherent to the primary 
disease and neutropenia caused by infiltration of bone 
marrow are at increased risk of CNS aspergillosis [10, 
11]. Patients with SCT run the high risk of aspergillosis 
because they are being treated with immunosuppression 
including high-dose steroids due to the possible spread of 
the Graft versus Host Disease (GvHD) [12]. Besides, anti-
fungal prophylaxis is recommended for these patients; 
however, prophylaxis could turn out to be unsuccessful, 
even with the first-line choices, in about 3–14% of all 
the patients exposed to invasive fungal infection [4, 13]. 
Therefore, patients with hematologic malignancies or 
SCT due to underlying disorders and immunosuppres-
sive therapies have a very high chance of developing CNS 
aspergillosis and antifungal prophylaxis may not prevent 
this infection. In addition, given the poor penetration of 
antifungal agents across the brain-blood barrier, their low 
concentration in brain tissue and Cerebro-Spinal Fluid 
(CSF), and their high toxicity, its mortality rate for these 
patients is quite high [14]. Since little is known about 
CNS aspergillosis in patients with leukemia or SCT, this 
systematic review aims to investigate the reported CNS 
aspergillosis cases in these patients.
Methods
Literature search and inclusion criteria
This study carried out a Medline search (via PubMed) 
from January 1, 1990 to August 30, 2020 with the search 
keywords obtained from the National Library of Medi-
cine’s Medical Subject Heading (MeSH) terms, abstracts, 
or titles by using Boolean Operators (and, or): “Asper-
gillus” or “Aspergillosis” and “Leukemia” or “Blood” or 
“Hematologic” or “Hematological” or “Haematologic” or 
“Haematological” or “Stem cell transplantation (SCT)” or 
“Bone marrow transplantation” or “Cytopenia” or “Leu-
kopenia” or “Neutropenia” and “Cerebral” or “Cranial” or 
“Central Nervous System (CNS)” or “Brain” or “Meningi-
tis”. Article references were reviewed and cross checked 
at length for any possible additional cases that might have 
been missed out or overlooked throughout the initial 
search. It is noteworthy to mention that non-English lan-
guage studies were excluded. The review protocol used in 
this study centers on the paper of Hickey et al. and our 
recent article [15, 16].
Inclusion criteria
All reports of CNS aspergillosis in patients with leukemia 
or SCT, full-text or abstract-only studies in English, and 
research works online in Medline (via PubMed) (from 
1990 until August, 2020) were eligible for study inclusion 
and they were carefully screened by both authors (AS 
and AM).
Exclusion criteria
The exclusion criteria comprised CNS infections with 
other fungi, review articles (either systematic or meta-
analysis), non-human study, guidelines, CNS aspergillosis 
in patients without leukemia or SCT, non-propagation 
of infection into the CNS, and inadequate reported data 
(Fig. 1).
Study selection and data extraction
As mentioned earlier, the two researchers (AS and AM) 
screened the articles and in case of any discrepancy, both 
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Fig. 1 Flow chart of publication selection and their inclusion in the systematic review
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researchers were obligated to scan the paper or confer-
ence abstract to ensure its eligibility for the review. Indi-
vidual case reports were considered so as to collect data 
about the epidemiology, clinical manifestations, treat-
ment, and diagnosis of CNS aspergillosis in patients with 
leukemia and SCT. Finally, the following features of each 
pertinent article were extracted and recorded by using 
Excel software (Microsoft, Redmond, WA, USA): coun-
try, year of publication, age, sex, causative fungal patho-
gen, leukemia, clinical presentation, treatment, surgery, 
diagnostic methods, and outcome.
Quality assessment
A critical appraisal checklist was employed for the case 
reports provided by the Joanna Briggs Institute (JBI) to 
carry out a quality assessment of the studies [17].
Results
Epidemiology
Sixty-seven cases were detected using searches through 
the PubMed bibliographic database as case reports. Five 
additional cases were identified and the above-cited ref-
erences were screened further. Then, thirteen cases were 
excluded because the leukemia cases of CNS aspergillo-
sis were not analyzed. Finally, 59 patients with leukemia 
or SCT and CNS aspergillosis were included in the final 
analysis based on the study criteria (Fig. 1). These cases 
of individuals were published from USA (14 reports), 
France (eight reports), Turkey (seven reports), Japan (six 
cases), Germany and Italy (four each), United Kingdom 
(three reports), Australia (two reports), Austria, Belgium, 
China, Czech, Greece, India, Iran, Netherlands, Portu-
gal, Spain, and Sweden (one each). Thus, Europe had 
the largest share of cases at 57.6% (34 reports), followed 
by the continents including Americas, Asia, and Aus-
tralia at 23.7% (14 reports), 15.3% (9 reports), and 3.4% 
(2 reports), respectively. No case from Africa was found. 
Our analysis also showed that 58.6% of the patients were 
male and the rest were female. The mean age of the 
patients was 36.1 years (ranged from 1.5–90 years), 62.7% 
of whom were under the age of 50 years (Table 1). Nota-
bly, 38.9% of these cases were 18 or younger.
The most common type of leukemia associated with 
CNS aspergillosis was ALL at 43.4% followed by Chronic 
Lymphocytic Leukemia  (CLL) and AML (two case with 
Acute promyelocytic leukemia  (APML,  APL)) at 27.4% 
and 23.5%, respectively (Fig.  2). Different transplanta-
tions were reported in 11 patients (18.6%) that include 
allogeneic bone marrow and SCT for aplastic anemia in 
four patients, allogeneic bone marrow transplantation for 
patient with CML, allogeneic SCT for two patients with 
multiple myeloma and AML, autologous SCT for breast 
cancer (two patients) and osteosarcoma and finally, cord 
blood transplantation for patients with AML (Table 1).
Our analysis showed that the total mortality rate in 
this cohort of published leukemia and SCT cases of 
CNS aspergillosis was 33% (19 cases) (two studies were 
omitted from final analysis due to the patients’ failure to 
adhere to proper follow-up). Among the dead patients, 
14 cases (24.5%) died of infection, while CNS aspergil-
losis was controlled in the other five patients and they, 
instead, died of hematologic disease progression (ALL 
and AML (each two cases) and CLL). The highest mortal-
ity rate was observed for patients with ALL (47.3%), fol-
lowed by AML (26.4%) and SCT for Aplastic anemia and 
multiple myeloma (15.7%). Notably, two patients with 
CLL and CML also died. Among the patients who died, 
52.7% were men and the rest were women. The mean age 
of the dead was 26.2 years (ranging from 1.5–59 years).
Only 29 studies (49%) performed species-level identi-
fication and found that A. fumigatus was the most com-
mon pathogen isolated from patients with 23 reports. A. 
felis, A. flavus, A. niger, A. nidulans, and A. terreus were 
the other pathogens isolated from patients. Noteworthy, 
A. fumigatus and A. niger were also isolated from the 
patients with pulmonary and cerebral aspergillosis and 
the mixed breakthrough invasive fungal infections caused 
the death of patients (Table 1).
Clinical manifestations
The most common presented manifestations were fever 
(59.3%), altered mental status (confusion, lethargy or loss 
of consciousness) (45.7%), headache (23.7%), hemipare-
sis (17%), facial palsy (8.4%), generalized seizure (10%), 
ataxia (5%), and focal seizure (6.7%). Imaging modali-
ties showed lung involvement in 57% of the patients, but 
chest pain was reported only in 8.4% of the cases. In this 
section, we have divided the duration of onset of clinical 
symptoms in patients after treatment into three catego-
ries: patients undergoing chemotherapy, ibrutinib, and 
transplant patients. The duration of onset of symptoms 
in patients who had undergone chemotherapy was deter-
mined in 22 cases and the average duration was 27.8 days 
(mean ± SD = 27.8 ± 16.8  days, ranging from 4 to 
80 days). The time of onset of symptoms in patients under 
ibrutinib therapy was reported in 10 cases with a mean 
duration of 5.9  months (mean ± SD = 5.8 ± 6  month, 
ranging from 15 days to 18 month). Finally, in transplant 
patients, symptoms developed over 4.9 months on aver-
age (mean ± SD = 4.8 ± 6.5  month, ranging from 1  week 
to 22  months) after transplantation. As mentioned, in 
more than half of the patients, pulmonary infection was 
also reported and the duration of the onset of CNS asper-
gillosis symptoms following the detection of lung involve-
ment was reported in 21 cases, which was 18.5 days on 
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average (mean ± SD = 18.5 ± 14.6  days, ranging from 
2 days to 2 months). Noteworthy, based on various clini-
cal and laboratory findings, brain lesions (abscess or 
multiple abscesses), cerebral blood vessel invasion with 
secondary infection or hemorrhage, and meningitis were 
the most common CNS disorders caused by Aspergillus 
species in patients at 86.4%, 18.6%, and 3.3%, respectively.
Diagnoses
The diagnosis was performed by histopathologic exami-
nation of different specimens in 23 of 59 (39%) instances. 
Furthermore, results obtained from culture and his-
topathologic examination led to the diagnosis of the 
infection in 11 (18.7%) patients. In three other cases, 
CNS aspergillosis was diagnosed post-mortem (5%) and 
culture results confirmed infection in three (5%) other 
patients. The samples used for diagnosis were obtained 
by craniotomy, stereotactic and burr hole biopsy, and 
laminectomy. In light of the formation of abscess capsule, 
transcranial puncture was not performed on one of the 
patients [18].
The results of culturing the CNS tissue samples 
were reported in 19 patients, of whom only three 
patients (15.7%) were tested negative. On the other 
hand, the results of CSF culturing were stated in 15 
cases and all of them were negative and only one posi-
tive case was reported in one patient with thoracic 
spinal cord intramedullary Aspergillus invasion. Our 
analysis also showed positive cultures from initial 
vitrectomy, subcutaneous nodules, and surgical joint 
biopsy. Finally, it should be noted that all blood cultures 
were negative.
With respect to laboratory tests, Aspergillus galac-
tomannan (GM) antigen assay was another diagnostic 
method that detected CNS aspergillosis in five (8.5%) 
other patients (lower limit for a positive result 0.5  ng/
mL). In one of these patients, negative CSF culture and 
polymerase chain reaction (PCR) disrupted the diagnosis 
process; however, serum and CSF samples tested positive 
for Aspergillus GM (more than 5.0), which led to correct 
identification of the cause of the infection and choice of 
an appropriate treatment [19]. Aspergillus GM results 
were stated in 28 cases. In this regard, the most positive 
results of this test were reported for serum (18 (72%) pos-
itive, 7 negative), bronchoalveolar lavage (BAL) (2 (50%) 
positive, 2 negative), and CSF (7 (43%) positive, 9 nega-
tive) samples, respectively. Aspergillus GM index was 
reported in 12 cases with an average of 3 ng/mL (Addi-
tional file 1: Table S3).
Positive results of CSF Aspergillus GM assay and PCR 
led to the diagnosis of infection in a patient, while Asper-
gillus was not isolated in the CSF [20]. On the other 
hand, in another case of a 15-year-old girl undergoing 
autologous SCT, parents were reluctant to agree to pro-
ceeding with brain biopsy and serologic markers of fun-
gal infection were negative. In this situation, fungal DNA 
was detected in the CSF by panfungal PCR assay using 
the primers derived from fungal 18S ribosomal RNA 
Fig. 2 Different leukemia in patient with CNS aspergillosis ((PubMed reported cases until August 2020). CLL Chronic lymphocytic leukemia. ALL 
Acute lymphoblastic leukemia. AML acute myeloid leukemia. CML Chronic myelogenous leukemia. APL Acute promyelocytic leukemia. T-ALL: acute 
T-lymphoblastic leukemia. T-LGL: T-cell large granular lymphocytic leukemia.
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(rRNA) genes [21]. Of note, only 11 (18.6%) patients were 
diagnosed with PCR, and CSF (four (57%) positive, three 
negative), tissue (two positive), BAL (one positive), and 
serum (two negative) samples were used for diagnosis 
(Fig.  3). It is noteworthy to mention that CSF examina-
tion (cell count, glucose level, and protein content) was 
carried out in 19 cases, the result of which was normal in 
ten patients (52.6%).
Medical  imaging modalities including Computed 
Tomography (CT) and Magnetic Resonance  Imag-
ing  (MRI) did not yield a definitive diagnosis for any of 
the patients. However, among the patients with imaging 
modalities, abscesses appearing as ring-enhancing lesions 
(post-infarct abscess formation) (57.6%), perifocal edema 
on MRI scan (marked T2-hyperintense peripheral edema 
and marked T1-hypointense peripheral edema) (56%), 
brain hemorrhages (3.3%), and nonspecific hyper intense 
foci (1.7%) were the most common signs reported. In 
the case of a Japanese patient with AML and Aspergillus 
meningitis, CT of the brain was unremarkable; however, 
MRI scans showed abnormal meningeal enhancement 
[20].
In 12 other patients (20.4%), pulmonary aspergillosis 
was diagnosed using BAL, bronchial washing and spu-
tum culture, and lung biopsy. In this regard, CNS asper-
gillosis was diagnosed only after pulmonary aspergillosis 
and observations of lesions in the CNS, and no specific 
diagnostic method was used to confirm CNS aspergil-
losis. Finally, thirty-six cases (61%) of CNS aspergillosis 
were presented with additional non-CNS sites of invasive 
aspergillosis. The affected sites among these cases were 
the lungs (34 cases), bone, kidneys, heart and thyroid 
gland (two each), eyes, sinus, liver, and intramuscular 
and subcutaneous abscesses (one each) (Additional file 1: 
Table S1).
Treatment
Various antifungal drugs have been used to treat CNS 
aspergillosis. The prevalent use of drug for treating this 
infection is amphotericin B (AMB) (76%), either deoxy-
cholate (DAMB) or liposomal AMB. In five patients, 
the use of DAMB showed a good therapeutic function. 
DAMB was combined with itraconazole and voriconazole 
(two cases) and was administered locally in the surgical 
cavity for two other patients. The combined use of lipo-
somal AMB with voriconazole and isavuconazole (every 
two cases) controlled infection in patients (Table  1). 
Notably, the AMB-resistant infection was reported in 
two patients. One of these patients had a DAMB-resist-
ant pulmonary and cerebral aspergillosis (during treat-
ment with humanized monoclonal antibody anti CD52), 
which was treated with voriconazole. Another patient 
in a case suffered a fatal CNS aspergillosis caused by A. 
terreus, an amphotericin-resistant mold, and he was mis-
takenly treated by empirical antifungal therapy including 
intrathecal AMB and then, died as a result [11, 22].
Voriconazole was another drug administered to a 
large number of patients (64%). According to our analy-
sis results, voriconazole has been used to treat CNS 
aspergillosis since 2003, whereas before this year, it was 
used only for a patient in a phase-II clinical trial. In this 
patient, DAMB was changed to LAMB due to renal 
toxicity; then, antifungal therapy was continued with 
itraconazole; however, due to the development of the 
paraventricular lesion and an additional lesion in the 
cerebellum, the patients were subsequently enrolled in 
a phase-II trial and then, received voriconazole [23]. 
On the other hand, voriconazole has not been adminis-
tered to 11 patients after 2003. In one of these patients, 
voriconazole could not be administered because of the 
hyperbilirubinemia; instead, DAMB was used, which did 
Fig. 3 Positive results obtained from various samples for the diagnosis of CNS aspergillosis in patients with leukemia and stem cell transplantation 
(PubMed reported cases until August 2020). CNS Central nervous system, CSF Cerebrospinal fluid, BAL Bronchoalveolar lavage, PCR Polymerase chain 
reaction
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not affect the treatment process and the patient died as a 
result [14] (the antifungal drugs used for these patients 
are listed in Table  1). Side effects of voriconazole were 
reported in nine patients (23%) such as severe cytolytic 
hepatitis, transient visual disturbances, reversible eleva-
tion of the alkaline phosphatase, respiratory insufficiency, 
gastrointestinal disturbances, significant photosensitivity, 
and nail changes. It should be noted that, voriconazole 
monitoring was performed in 14 (36.8%) patients and the 
duration of using this drug by patients was reported in 16 
cases with an average of 10.7 months.
Among the patients that were treated by voriconazole, 
the antifungal agent did not exhibit proper therapeutic 
function effects in 12 patients (31.5%) [3, 4, 10, 22, 24–
31]. In four of these patients, the antifungal agent was 
replaced with other drugs due to its possible side effects 
[10, 24–26]. Besides, in another patient, voriconazole 
was replaced by isavuconazole due to coinfection with 
Mucorales [32]. Voriconazole in 58.3% of these patients 
was not monitored. Finally, the combined use of vori-
conazole and liposomal AMB (three cases), caspofungin 
(there cases), DAMB (two cases), and micafungin led to 
controlling CNS aspergillosis [2, 33–40]. In addition, in 
a patient with CLL, signs of intracranial hyper-tension 
with generalized seizure were developed despite tak-
ing voriconazole. Prednisone (40  mg/day) was added to 
this antifungal agent which led to the gradual improve-
ment of the patient’s condition [37]. In addition to AMB 
and voriconazole, other antifungals such as caspofungin 
(11 cases), itraconazole (nine cases), isavuconazole (five 
cases), flucytosine and micafungin (four each), flucona-
zole, and posaconazole (three each) were used (Table 2). 
Notably, prophylactic  and empirical antifungal agents 
were used for treatment to control fungal infections in 
patients with leukemia or SCT. However, in almost all 
of the cases, no improvement was achieved (Additional 
file 1: Table S2).
Besides antifungal therapy, surgical intervention 
appears to have a key role in the treatment of CNS asper-
gillosis. Surgery was used in 23 (39%) patients. These 
surgeries included Craniotomy with aspiration and resec-
tion of brain abscesses, stereotactic resection, aspira-
tion, and drainage. Besides, one female patient with ALL 
underwent T11–L1 laminectomy and ultrasound-guided 
aspiration for her intramedullary and extra medullary 
abscesses [28]. The main surgical finding was a vascular-
ized thick capsule (soft capsule) containing a necrotic 
purulent component, pinkish white pus or viscous fluid 
[25, 41, 42]. In one patient, after five weeks of DAMB use, 
the patient’s symptoms worsened; therefore, resection 
of the inferior temporal lobe abscesses and debridement 
of the external canal, petrous apex, and mastoid air cells 
were performed, which led to control of the infection 
and recovery of the patient [5]. On the other hand, a 
patient with SCT underwent total surgical removal of 
the cerebellar abscess with suboccipital craniectomy; 
however, after 5 weeks, the scan again revealed an intra-
cerebellar abscess. In this condition, the patient under-
went reoperation and was treated with locally DAMB 
and itraconazole [43]. Stereotactic or open surgery were 
recommended in five patients, which was not possible 
due to severe thrombocytopenia and underlying hema-
tological conditions, critical localization of the lesion, in 
light of the formation of abscess capsule and the patient’s 
general condition [2, 3, 18, 31, 33]. In another patient, the 
neurosurgical procedure was not considered due to the 
risk that the organism would penetrate the brain; how-
ever, the patient successfully recovered with catheter coil 
embolization and long-term antifungal agents [44].
Discussion
Aspergillus species are common contaminants of the 
upper respiratory tract with initial colonization occur-
ring in the nasopharynx or lower respiratory tree. How-
ever, in patients with leukemia or prolonged neutropenia, 
Table 2 Confirmation methods and treatment of CNS 
aspergillosis in patients with leukemia or stem cell 
transplantations
Confirmation methods
 Histopathological examination (HE) 39%
 HE and culture 18.70%
 Culture 5%
 Post-mortem 5%
 Aspergillus galactomannan (GM) 8.50%
 GM assay and PCR 1.70%
 PCR 1.70%
 Non-CNS samples 20.40%
Medical imaging modalities
 Ring enhancing lesions 57%
 Perifocal edema on MRI 56%
 Brain hemorrhages 3.30%
 Nonspecific hyper intense foci 1.70%
Treatment
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hematogenous dissemination from the lung and second-
ary cerebral aspergillosis cause a significant mortality 
rate [6, 7]. Recent study reported acute leukemia as the 
most common underlying disease in patients with fungal 
infections of the CNS and paranasal sinuses [62] and our 
results also showed ALL as the most common leukemia 
in patients. In the present study, the overall mortality was 
34%; however, the mortality attributed to CNS aspergillo-
sis was 24.5%. On the other hand, in a systematic review 
of reported cases (ninety cases recorded up to June 2005) 
on CNS aspergillosis in children, as published by Dotis 
et  al., the overall mortality rate was 65.4% [63]. Such a 
high mortality rate can be related to the screening of the 
disease in infants and children, the unavailability of anti-
fungal such as voriconazole, and the screening of patients 
with all the underlying disorders. In this regard, two 
recent studies have reported 33% and 48% mortality rates 
for invasive fungal infections of the CNS. They suggested 
that the mortality remained high; however, compared to 
previous historical data, it seemed to have been reduced, 
probably due to the availability of newer antifungal drugs, 
immune response in histopathology, absence of co-
infections, corticosteroid tapering, and possibly surgical 
drainage [62, 64].
From the data available in the literature, altered men-
tal status, hemiparesis, cranial nerve palsies, and seizures 
were the clearest manifestations of CNS aspergillosis. 
Besides, our results showed lung involvement in more 
than half of the patients and 61% of the cases presented 
with additional non-CNS sites of invasive aspergillosis. 
These results should motivate clinicians to rule out CNS 
aspergillosis quickly and efficiently in patients suffering 
pulmonary aspergillosis [41]. In this regard, in a patient 
with AML, before the initiation of induction chemo-
therapy, MRI of the brain was conducted and it did not 
detect any intraparenchymal brain abnormalities. How-
ever, 16  days after induction chemotherapy, the patient 
developed pulmonary symptoms and three days later, 
brain involvement occurred [22]. Therefore, the onset of 
CSN aspergillosis in patients with leukemia and immu-
nodeficiency is very rapid, which requires greater control 
and following up of patients. Ibrutinib has been used in 
recent years to treat CLL patients. Our results showed 
that, CNS aspergillosis in patients occurs 6  months, on 
average, after ibrutinib use, suggesting that CNS is a 
safe haven for invasive aspergillosis in all CLL-induced 
patients treated with ibrutinib. In this respect, meticu-
lous and repeated neurological examinations and fast 
diagnosis are needed for patients with invasive aspergil-
losis after ibrutinib treatment, with a very low threshold 
for prescribing MRI of the brain [37].
Given that the clinical signs of CNS aspergillosis 
are usually nonspecific and similar to other diseases, 
differential diagnosis such as lung cancer, cerebral infec-
tion or abscesses such as listeriosis, cryptococcal and 
tuberculous meningitis, metastatic disease and cerebral 
malignancy should be considered when imaging modali-
ties are used for diagnosis in patients [39]. Noteworthy, 
the MRI appearance of CNS aspergillosis depends on 
different factors such as the timing of neuroradiologic 
assessment, immunologic status of the patient, and the 
characteristics of the fungus [42]. However, our results 
showed that on conventional MRI sequences in patients 
with leukemia, CNS aspergillosis appears as ring-enhanc-
ing lesions, with perifocal edema on MRI. Brain CT has 
not proven useful in the case of Aspergillus meningitis, 
which has no parenchymal lesions, while Gadolinium-
enhanced MRI of the brain ensures a more efficient diag-
nosis of the infection [20, 65]. As mentioned earlier, CSF 
analysis was normal in most of the patients because neu-
tropenic patients with fungal meningitis do not always 
show elevation of the CSF cell count [20]. Therefore, 
imaging modalities are subject to many limitations for 
accurate diagnosis of CNS aspergillosis; but, if CT and 
MRI are indicative of cerebral lesions and infarction and 
vascular inflammation in an immune-compromised host, 
a fungal etiology must be considered, even if CSF exami-
nation does not reveal any abnormalities [7].
Histopathological examination and the use of brain 
biopsy have been the most commonly used diagnostic 
methods for patients; however, given that a large num-
ber of patients are children, parents are often reluctant to 
proceed with brain biopsy [21]. In addition, due to coagu-
lation issues and underlying hematological conditions, 
applying an invasive diagnostic procedure is not always 
feasible for patients with leukemia [3]. In this regard, a 
study reported that performing MR-guided biopsy of 
the suspected brain lesion can yield a more precise tis-
sue diagnosis and its feasibility is proven for sick leuke-
mia patients during remission induction and it allows for 
intra-lesional local instillation of drugs required [10]. On 
the other hand, even with a proper biopsy, histopatholog-
ical examinations may not show the diagnostic features 
of fungal infections [45]. Besides, it is quite challenging 
to make a diagnosis of CNS aspergillosis on a histomor-
phological basis and the most prevalent cause for incor-
rect morphological diagnosis is the misidentification 
of Mucorales as Aspergillus spp [66, 67]. Due to mixed 
mold infection and antifungal resistance, identification 
of Aspergillus at the species level should be considered 
in multiple site involvement [4]. Therefore, histopatho-
logical examination of different samples has limitations 
for diagnosis and for some patients, other ways such as 
culture and molecular methods should be used for the 
species-level identification and definitive diagnosis of 
infection.
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Culture was used to diagnose CNS aspergillosis in 
23% of the patients. It should be mentioned that in some 
patients, prolonging the culture time of the microor-
ganism reduces the diagnostic value of this method. For 
example, in a patient with APL, the histologic evalua-
tion proved diagnostic for aspergillosis, while the cul-
tures became positive only 3 weeks later [5]. In addition, 
even after identifying a mold on the culture media, it still 
requires several more days to detect the fungus at the 
species level [22]. Our results showed that when sam-
ples obtained from biopsy or surgery were used for cul-
ture, there was a higher chance of isolating Aspergillus, 
while the use of CSF was not very desirable for culture. 
In this context, as mentioned, obtaining tissue samples 
in patients with leukemia is highly restricted. Therefore, 
because early identification of opportunistic invasive fun-
gal pathogens has been shown to guide interventions and 
affect prognosis, culture may be limited in patients with 
challenging conditions.
In this regard, the use of molecular methods for diag-
nosing the cause of infection and drug resistance can be 
helpful. The use of PCR should be considered in two situ-
ations: (A) when the levels of fungi in both blood and CSF 
are below the lower limit of detection by conventional 
diagnostic assays; (B) when an uncommon fungal patho-
gen, which remains undetected by conventional diagnos-
tic assays, infects the CNS [21]. In a patient with AML, A. 
terreus was detected using PCR and Electrospray Ioniza-
tion with Mass Spectrometry. This pathogen is inherently 
resistant to AMB and rapid diagnosis can prevent thera-
peutic fractures in patients [22]. Therefore, timely identi-
fication of CNS aspergillosis by molecular methods can 
lead to the institution of pathogen-specific and directed 
therapy and should be used more in patients.
Aspergillus GM assay was another diagnostic method 
for diagnosing infection in 8.4% of the patients. The GM 
test is an enzyme-based immunological method used to 
determine the GM exo-antigen of Aspergillus species in 
the cell wall [35]. Recent studies have reported low sen-
sitivity to PCR, considering that only a small number of 
fungal cells are observed in the CSF. Alternatively, GM 
assay in the CSF was considered to be the most useful 
[19, 65, 68]. However, our results showed the superior-
ity of PCR in detecting CNS aspergillosis from CSF sam-
ples. Moreover, present study demonstrated that serum 
and BAL samples were more suitable for performing GM 
assay than CSF. Notably, GM assay showed cross-reac-
tivity with other hyalohyphomycetes such as Fusarium 
[69, 70]. However, when culture and PCR of CSF were 
negative in one patient, GM assay alone led to a correct 
diagnosis of the infection. Furthermore, decline of the 
GM antigen titer during treatment corresponded to the 
clinical response to treatment [19, 65]. More importantly, 
accurate diagnosis using GM assay demands multiple 
sampling and serial Aspergillus GM monitoring is useful 
in the early detection of relapse and reinitiation of anti-
fungal therapy [27]. Thus, as mentioned before, each of 
the diagnostic methods of CNS aspergillosis in patients 
with blood malignancies has advantages and limitations. 
Therefore, if possible, using the most appropriate sam-
ple for each test can increase the chances of detecting a 
fungal infection. Clinicians should use diagnostic meth-
ods according to the patients’ condition to ensure correct 
diagnosis of the infection.
After proper and timely diagnosis, the use of appro-
priate antifungal drugs is also very important. AMB 
and voriconazole are the most commonly used antifun-
gals in patients with CNS aspergillosis. AMB, the echi-
nocandins, itraconazole, and posaconazole are large 
molecules and the penetration of these drugs across the 
blood–brain barrier is mainly limited. Fluconazole and 
5-fluorocytosine penetrate well into the CNS; however, 
Aspergillus frequently exhibits resistance to these anti-
fungal agents [71]. Voriconazole displays a broad range 
of antifungal activities and facilitates CNS penetration. 
The 2017 ESCMID guidelines recommend voriconazole 
as the first-line agent for “proven” or “probable” aspergil-
losis treatment in all children [72]. However, our analysis 
showed that good results were not obtained in one-third 
of patients treated with voriconazole.
Therapeutic Drug Monitoring (TDM) is highly rec-
ommended when voriconazole is used, because achiev-
ing therapeutic concentrations in a timely manner can 
be challenging due to nonlinear pharmacokinetics and 
observed inter-patient variability. In this regard, it is still 
difficult to find the most effective, yet tolerated, dose, 
primarily due to the poor correlation between dose and 
serum concentration. Our results showed that TDM 
of voriconazole has not been performed for a range of 
patients which could be due to limited access to the 
serum voriconazole level testing and slow turnaround 
time. Most significantly, individuals with sub-therapeutic 
concentrations are at increased risk of mortality. On the 
other hand, high voriconazole concentrations may cause 
adverse effects like neurotoxicity and hepatotoxicity [3, 
61, 73]. Furthermore, clinicians should be cognizant of 
the drug-drug interaction between voriconazole and cor-
ticosteroids for cytochrome P450 isoenzymes, CY3A4, 
CYP2C9, and CYP2C19, which can lead to decreased 
plasma voriconazole concentrations and, thus, limited 
efficacy against the Aspergillus [10, 31]. Therefore, to 
prevent voriconazole therapy failure, it is imperative to 
attain therapeutic voriconazole plasma concentrations 
promptly in order to achieve a favorable response and 
also, is necessary to perform a CYP2C19 genotype test 
to determine the genetically predicted metabolizer status 
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can prevent therapeutic failures when voriconazole is 
used.
In some patients, the use of combination therapy 
showed good performance. However, characterization 
of patients benefiting from a combination antifungal 
therapy is required and confirmatory results of further 
prospective studies are needed before the combination 
therapy of antifungal agents can be fully accepted as 
standard strategies for CNS aspergillosis. Lastly, there 
are no clear recommendations as to the exact duration 
of antifungal treatment of mold infections of the CNS. 
However, antifungal chemotherapy is usually recom-
mended until the resolution of all clinical, laboratory, and 
radiographic findings of active infection [52]. Besides, 
following the treatment of CNS aspergillosis in leukemia 
patients, prolonged and, in some cases, lifelong second-
ary prophylaxis may be necessary after the initial treat-
ment [27].
Neurosurgical intervention was used in 39% of the 
patients. One study reported that the use of image-
guided stereotactic neurosurgery provided a safe and 
vital component in the successful treatment of patients’ 
devastating conditions [41]. In another patient with 
bone marrow transplantation, despite the administration 
of AMB, flucytosine, and micafungin, the patient died 
2  months after transplantation. The authors suggested 
that if the infected lesion remains after antifungal agent’s 
therapy, surgical drainage or resection of infected tissue 
along with systemic therapy may be important. In this 
regard, Infectious Diseases Society of America (IDSA) 
guidelines recommend surgical drainage and infected 
tissue removal along with systemic antifungal therapy 
for patients suffering from CNS aspergillosis [52]. There-
fore, using a combination of antifungals along with sur-
gery can help control the infection. In some cases, due 
to the critical localizations of the lesion and underlying 
hematological conditions, surgery is not possible. In this 
situation, the use of antifungal agents continues for a very 
long time [2].
Finally, in addition to surgical intervention and antifun-
gal treatment, patient induction chemotherapy manage-
ment, parallel resolution of neutropenia, and complete 
remission of leukemia undoubtedly play an important 
role in treating patients. A female patient with CLL was 
treated with voriconazole after being diagnosed with 
CNS aspergillosis. Then, she received bendamustin for 
CLL progression, leading to more profound neutrope-
nia and clinical deterioration [26]. Therefore, along with 
the mentioned treatments, it is important to control the 
patient’s underlying conditions, which can facilitate the 
treatment process. For instance, discontinuing immu-
nosuppressive drugs, if possible, can help control CNS 
aspergillosis.
Conclusion
CNS aspergillosis is a highly lethal disease in patients 
with blood malignancies and is subject to a very poor 
prognosis. Patients with leukemia are very sensitive to 
fungal infections due to underlying disorders and sev-
eral previous chemotherapy regimens. In this regard, 
pulmonary involvement in these patients usually occurs 
shortly after the start of chemotherapy and after that, 
CNS infections may occur as an occult asymptomatic 
extra-pulmonary involvement during the diagnostic 
evaluation of febrile neutropenic patients or sympto-
matic form, which usually develop after a few weeks 
of pulmonary manifestation. Therefore, systematic full 
screening including CT scan and enhanced MRI for 
CNS lesions should be performed for every diagnosis 
of invasive fungal infection; in addition, when infection 
is suspected in these patients, a definitive and differen-
tial diagnosis should be made using various diagnostic 
methods. If possible, species identification of the fun-
gus is suggested because the occurrence of antibiotic 
resistance in some species can completely change the 
treatment regimen. In addition, the use of combination 
therapies should be considered in future studies so that 
if the first line of the treatment fails, the most appro-
priate treatment strategy can be adopted for patients. 
Furthermore, in addition to using appropriate antifun-
gal therapy and TDM, control of patients’ chemother-
apy should also be considered because the outcome of 
invasive aspergillosis is poor unless immunologic status 
improves.
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